Dow Jones Newswires: AstraZeneca-Daiichi Sankyo Enhertu breast cancer drug recommended for EU approval
The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
